Global Neurodegenerative Disease Market Report 2023: Sector is Expected to Reach $52.7 Billion by 2030 at a CAGR of 3.2%

Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Neurodegenerative Disease Market, By Indication Type, By Drug Type, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides in-depth analysis of the global neurodegenerative disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.

Company Profiles

• Abbvie Inc.
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International Gmbh
• Hoffmann-La Roche
• Merck & Co. Inc.

Neurodegenerative disease is a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in a process known as neurodegeneration. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. Neurodegenerative disorders usually get worse over time and have no cure.

Rise in prevalence of neurodegenerative diseases, growing geriatric population, rise in demand for safe and effective therapeutics, increasing public awareness about neurodegenerative disease and available therapeutics, and strong product pipeline are major factors expected to propel growth of the global neurodegenerative disease market over the forecast period.

For instance, in October 2022, Cyclo Therapeutics announced the launch of a Phase 2b study for its investigational drug, named Trappsol Cyclo, which targets the reduction of amyloid beta and tau to treat early Alzheimer's disease.

Moreover, in August 2022, Amneal Pharmaceuticals submitted a New Drug Application to the Food & Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.

Key Features of the Study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global neurodegenerative disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global neurodegenerative disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodegenerative disease market.

Key Attributes:

Market Segmentation

by Indication Type:

• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Other Indication Types

by Drug Type:

• N-methyl-D-aspartate Receptor antagonists
• Cholinesterase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drugs
• Other Drug Types

by Geography:

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

For more information about this report visit https://www.researchandmarkets.com/r/xbkx0w

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Global Neurodegenerative Disease Market